Introducing
Precisebreast
PreciseBreast™ is designed specifically to speed the process of care planning for breast cancer patients.
PreciseBreast uses AI-image analysis and Morphology Feature Array® to predict the likelihood of tumor recurrence within hours, improving the multi-disciplinary team’s workflow.
PreciseBreast was previously validated on a Mount Sinai Health System cohort published in Breast Cancer Research, 2022. A further study, presented at SABCS 2024 extends these findings in a gene expression tested cohort from Baptist Health Miami Cancer Institute in partnership with COTA, Inc. Trials are ongoing that aim to validate PreciseBreast for predicting treatment benefit.
Early-Stage Invasive Ductal Carcinoma, Hormone-Receptor Positive, HER2-Negative, Node Negative or 1-3 Nodes Positive
View Full Poster
how precisebreast works
PreciseBreast deploys AI to analyze the cellular morphology of tissue samples already collected – the same slides pathologists use for tumor grading. The Morphology Feature Array® then objectively classifies patients into two cohorts of low and high risk of tumor recurrence in ~48 hours at 30% the cost of gene expression testing. Oncologists can now confidently discuss results weeks faster than in the past to relieve patient anxiety and to allow for a more comprehensive shared decision making process.
With PreciseBreast, patients - and their physicians - gain clarity, peace of mind, and an objective data point to base decisions on weeks sooner than they would with tumor grading and gene expression testing alone.
Healthcare systems benefit with meaningful cost savings generated by the low risk patients who may not need further expensive gene expression testing.
PreciseBreast requires no additional procedures or specialized staff for specimen collection, and it can be accessed from any geographical area in the US or the world.
Analytic validation of the PreciseBreast technology
98%
Precision & Reproducibility
Tumor Segmentation
<2%
Variation of Assay Risk Score
Analytical validation of PreciseBreast demonstrates high precision across key factors (Fernandez, G., Zeineh, J. et al. Clinical Breast Cancer 2023 (NYSDOH))
Using PreciseBreastTM as well as gene expression or visual pathologic analysis delivers benefits for patients, physicians, and payors.
.svg)
Data to drive precise reporting of tumor recurrence risk
Faster results lessen anxiety for patients
.svg)
Lower overall costs for treatment and testing
Availability to 100% of eligible patients
Nov 20, 2024
World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio
See More
Nov 20, 2024
World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio
See More
Aug 21, 2024
PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments
See More
Aug 21, 2024
PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments
See More
Aug 2, 2024
As AI-Based Diagnostics Proliferate, Stakeholders Strive for Regulation Without Stifling Innovation
See More
Aug 2, 2024
As AI-Based Diagnostics Proliferate, Stakeholders Strive for Regulation Without Stifling Innovation
See More
Jul 23, 2024
PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast™(PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics
See More
Jul 23, 2024
PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast™(PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics
See More
Contact us today to learn more about PreciseBreast.
